Moderna Inc.
Moderna Announces R&D Updates and Financial Framework Extension
Summary
Moderna, Inc. announced program and financial updates at its annual R&D Day event on September 12, 2024. The Company expects to submit three respiratory vaccines for approval in 2024 and announced positive Phase 3 results for its RSV and standalone flu vaccines. Moderna also presented its strategic prioritization of its mRNA pipeline and expects to reduce annual research and development expense by approximately $1.1 billion starting in 2027. Additionally, the Company updated its financial framework through 2028.
Profitelligence Alerts
Get alerts for MRNA
Be first to know when Moderna Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Moderna Inc.
Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.
Official SEC Documents
Advertisement